Abstract
Introduction: Sarcomatosis is the disseminated intraperitoneal spread of sarcoma. It is a condition for which there is no effective treatment. Photodynamic therapy (PDT) is a cancer treatment modality that uses a photosensitizing agent and laser light to kill cells. We report our preliminary Phase II clinical trial experience using PDT for the treatment of intraperitoneal sarcomatosis.
Methods: From May 1997 to December 1998 eleven patients received twelve PDT treatments for intraperitoneal sarcomatosis. Photofrin® (PF) 2.5 mg/kg was administered intravenously 48 hours before surgical debulking to a maximum residual tumor size of less than 5 mm. Light therapy was administered at a fluence of 2.5 J/cm2 of 532 nm green light to the mesentery and serosa of the small bowel and colon; 5 J/cm2 of 630 nm red light to the stomach and duodenum; 7.5 J/cm2 of red light to the surface of the liver, spleen, and diaphragms; and 10 J/cm2 of red light to the retroperitoneal gutters and pelvis. Light fluence was measured with an on-line light dosimetry system. Response to treatment was evaluated by abdominal CT scan at 3 and 6 months, diagnostic laparoscopy at 3 to 6 months, and clinical examination every 3 months.
Results: Adequate tumor debulking required an omentectomy in eight patients (73%), small bowel resection in seven patients (64%), colon resection in four patients (36%), splenectomy in one patient (9%), and a left spermatic cord resection in one patient. Five patients (45%) have no evidence of disease at follow-up (range, 1.7–17.3 months), including patients at 13.8 and 17.3 months examined by CT. Two patients (18%) died from disease progression. Four patients (36%) are alive with disease progression. Toxicities related to PDT included substantial postoperative fluid shifts with volume overload, transient thrombocytopenia, and elevated liver function tests. One patient suffered a postoperative pulmonary embolism complicated by adult respiratory distress syndrome (ARDS).
Conclusions: Debulking surgery with intraperitoneal PDT for sarcomatosis is feasible. Preliminary response data suggest prolonged relapse-free survival in some patients. Additional follow-up with more patients will be necessary for full evaluation of the added benefit of PDT and aggressive surgical debulking in these patients.
Similar content being viewed by others
REFERENCES
Storm FK, Eilber FR, Mirra J, Morton DL. Retroperitoneal sarcomas: reappraisal of treatment J Surg Oncol 1981; 17: 1 –7
Kinsella TJ, Sindelar WF, Lack E, Glatstein E, Rosenberg SA. Preliminary results of a randomized study of adjuvant radiation therapy in resectable retroperitoneal soft tissue sarcomas. J Clin Oncol 1988; 6: 18 –25
Foote CS. Mechanisms of photooxygenation. Prog Clin Biol Res 1984; 170: 3 –18
Gomer CJ, Dougherty TJ. Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 1979; 39: 146 –51
Biel MA. Photodynamic therapy and the treatment of head and neck cancers. J Clin Laser Med Surg 1996; 14: 239 –44
Grant WE, Speight PM, Hopper C, et al. Photodynamic therapy: an effective, but non-selective treatment for superficial cancers of the oral cavity. Int J Cancer 1997; 71: 937 –42
Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72: 595 –602
Kato H, Okunaka T, Shimatani H. Photodynamic therapy for early stage bronchogenic carcinoma. J Clin Laser Med Surg 1996; 14: 235 –8
McCaughan JS, Williams TE. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J Thorac Cardiovasc Surg 1997; 114: 940 –7
Mostal TL, Dougherty TJ, Urschel JD, et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 1998; 66: 1128 –33
Pass HI, Delaney T, Tochner Z, et al. Intrapleural photodynamic therapy Ann Surg Onc 1996; 1: 28 –37
Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995; 42: 507 –12
McCaughan JSJ, Nims TA, Guy JT, Hicks WJ, Williams TEJ, Laufman LR. Photodynamic therapy for esophageal tumors. Arch Surg 1989; 124: 74 –80
Likier HM, Levine JG, Lightdale CJ. Photodynamic therapy for completely obstructing esophageal carcinoma Gastrointest Endosc 1991; 37: 75 –8
Marcon NE. Photodynamic therapy and cancer of the esophagus. Semin Oncol 1994; 21: 20 –3
Overholt BF, Panjehpour M. Barrett’s esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995; 42: 64 –70
Laukka M, Wang K. Initial results using low-dose photodynamic therapy in the treatment of Barrett’s esophagus. Gastrointest Endosc 1995; 42: 59 –63
Muller PJ, Wilson BC. Photodynamic therapy of malignant primary brain tumours: clinical effects, post-operative ICP, and light penetration of the brain. Photochem Photobiol 1987; 46: 929 –35
Sperduto PW, DeLaney TF, Thomas G, et al. Photodynamic therapy for chest wall recurrence in breast cancer. Int J Radiat Oncol Biol Phys 1991; 21: 441 –6
Schuh M, Nseyo UO, Potter WR. Photodynamic therapy for palliation of locally recurrent breast carcinoma J Clin Oncol 1987; 5: 1766 –70
Benson RC. Treatment of diffuse transitional cell carcinoma in situ by whole bladder hematoporphyrin derivative photodynamic therapy. J Urol 1985; 134: 675 –8
Harty JI, Amin M, Wieman TJ, Tseng MT, Ackerman D, Broghamer W. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Urol 1989; 141: 1341 –6
Tochner Z, Mitchell JB, Harrington FS, Smith P, Russo DT, Russo A. Treatment of murine intraperitoneal ovarian ascitic tumor with hematoporphyrin derivative and laser light. Cancer Res 1985; 45: 2983 –7
Tochner Z, Mitchell JB, Smith P, Harrington F, Glatstein E, Russo D, Russo A. Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer 1986; 53: 733 –6
Sindelar WF, DeLaney TF, Tochner Z, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Phase I study. Arch Surg 1991; 126: 318 –24
DeLaney TF, Sindelar WF, Tochner Z, et al. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993; 25: 445 –57
Sindelar WF, Sullivan FJ, Abraham E, et al. Intraperitoneal photodynamic therapy shows efficacy in phase I trial Proc Am Soc Clin Oncol 1995; 14: 447. Abstract 1550
Kilkenny JW 3rd, Bland KI, Copeland EM 3rd. Retroperitoneal sarcoma: the University of Florida experience J Am Coll Surgeons 1996; 182: 329 –39
Karakousis C, Gerstenbluth R, Kontzoglou K, Driscoll DL. Retroperitoneal sarcomas and their management. Arch Surg 1995; 130: 1104 –9
Heslin M, Lewis J, Nadler E. et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management J Clin Oncol 1997; 15: 2832 –9
Engbrecht BW, Menon C, Kachur AV, Hahn SM, Fraker DL. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res 1999; 59: 4334 –42
Nambisan RN, Karakousis CP, Holyoke ED, Dougherty TJ. Intraoperative photodynamic therapy for retroperitoneal sarcomas. Cancer 1988; 61: 1248 –52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bauer, T.W., Hahn, S.M., Spitz, F.R. et al. Preliminary Report of Photodynamic Therapy for Intraperitoneal Sarcomatosis. Ann Surg Oncol 8, 254–259 (2001). https://doi.org/10.1007/s10434-001-0254-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0254-7